Navigation Links
Sirion Therapeutics Announces Clinical Data to be Presented at the,2007 Association for Research in Vision and Ophthalmology (ARVO),Annual Meeting

veloping and commercializing ophthalmic therapies for unmet needs."

    Sirion Therapeutics Reception for all ARVO attendees:


    A company update and presentation by Sirion Therapeutics' senior

    executives

    Date: Tuesday, May 8, 2007, 7:30 p.m. -- 9:00 p.m.

    Venue: Ft. Lauderdale Grande

    For additional information, contact Mary Leaper at

     or register online at

    www.siriontherapeutics.com/ARVO and use the password VISION.



    ARVO poster presentations featuring ST-601 (difluprednate):


    Preclinical Pharmacokinetics of Difluprednate Emulsion

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B741, Program Number: 2651


    Ocular Distribution and Metabolism after Instillation of Difluprednate

     Ophthalmic Emulsion in Rabbits

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B744, Program Number: 2654


    Preclinical Toxicity of Difluprednate Emulsion

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B743, Program Number: 2653


    Efficacy of Difluprednate Ophthalmic Emulsion in Preclinical Studies of

     Uveitis

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B742, Program Number: 2652


    Difluprednate Emulsion Inhibits Postoperative Inflammation in Rabbit

     Paracentesis Model

    Session Date: Tuesday, May 8, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B745, Program Number: 2655


    A Phase III, Non-Inferiority Study of Difluprednate Ophthalmic Emulsion

     (DFBA), 0.05% in the Treatment of Anterior Uveitis

    Session Date: Wednesday, May 9, 2007, 8:30 a.m. - 10:15 a.m.

    Posterboard Number: B808, Program Number: 3904


    A Phase III, Open-Label, Clinical Study of Difluprednate Ophthalmic

     Emulsion (DFBA), 0.05% in the Treatment of Severe Refractory Anteri
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Sirion Therapeutics Receives Orphan Drug Designation for Ophthalmic Drug to Treat Viral Eye Infection
2. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
3. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
4. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
9. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
10. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
11. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
Post Your Comments:
(Date:1/15/2014)... BOSTON , Jan. 15, 2014 Tegra Medical is ... Mark King as its new Chief Executive Officer.  Mark ... in which he has overseen the company,s four facilities in ... and Costa Rica.  Mr. King joined Tegra Medical in 2012 ...
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
Breaking Medicine Technology:Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18
... Bermuda, Dec. 16 Celtic Pharmaceutical Holdings L.P. ("Celtic ... preliminary analyses completed on the two double-blinded studies of XERECEPT ... edema, as well as an initial database lock on the ... , The results of these studies ...
... Live Broadcast on December 18, 2008 at 9 a.m. Eastern Time ... MannKind Corporation (Nasdaq: MNKD ) will host ... 3 studies of AFRESA(TM), the company,s ultra rapid acting, inhaled insulin product, ... , , To participate in the live ...
Cached Medicine Technology:Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009 2MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes 2
(Date:4/18/2014)... of Medicine researchers have been awarded two-year grants for ... announced this month. Of the 110 initial submissions to ... Forum Program, only four projects were funded, three of ... Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; and ... professor of oncology, will use his $500,000 proof of ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... pain relief targets that could be used to ... King,s College London made the discovery when researching ... of the body. , Dr Marzia Malcangio said: ... pain generation and our findings could help chemotherapy ... One potential side effect of some chemotherapy drugs ...
(Date:4/17/2014)... (April 17, 2014) Two recent papers by ... and colleagues may help scientists develop treatments or ... fever, Japanese encephalitis and other disease-causing flaviviruses. , ... and molecular genetics at the School of Medicine ... Hughes Medical Institute, and colleagues recently published articles ...
(Date:4/17/2014)... who treat patients with a severe and progressive ... agonizing treatment decision. , The drug sirolimus can ... shortness of breath. But some patients eventually may ... fatal complications following transplantation. , "It,s a terrible ... of Loyola University Medical Center,s LAM Clinic and ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... 21 BET News correspondent, Andre Showell will lead the discussion during ... Wednesday, July 22 ( ) at 8 ... broadcast of the entire news conference along with pre and post analysis ... The President is expected to discuss health care legislation and ...
... LOUIS, July 21 Young Innovations, Inc. (Nasdaq: YDNT ) ... $0.04 per share, payable September 15, 2009 to all shareholders of record ... of up to 500,000 shares of the Company,s stock. This authorization, which ... scheduled to expire on July 31, 2009. , , ...
... , , FRANKLIN, Tenn., July 21 ... documentation technology and services, today announced details for the release of its ... , Spheris plans to issue its earnings ... trading on Thursday, August 6, 2009, and will host a conference call ...
... , , HOUSTON, July 21 ... of fiscal 2009 on Thursday, August 6, 2009. , , ... at 11 a.m. ET following distribution of the earnings release. Additional information will ... the News Room on the day of the earnings announcement. , ...
... Ill., July 21 Since 2003, the University HealthSystem Consortium (UHC) has ... the sixth consecutive year. The Honor Roll publicly recognizes and celebrates all ... , All Honor Roll recipients must exhibit 10 ... a work environment founded on dignity and respect for all employees , ...
... MEQUON, Wis., July 21 Wonderbox Technologies has ... to benefit from continued advances in technology and software features. ... designed for managed care benefit administration and case management. The ... scheduling, managing, and monitoring day-to-day care tasks and case assignments. ...
Cached Medicine News:Health News:BET Networks Airs Special Coverage of President Obama's News Conference on Health Care 2Health News:Young Innovations, Inc. Board of Directors Declares Quarterly Dividend and Authorizes Share Repurchase Program 2Health News:Spheris Sets Second Quarter 2009 Earnings Release and Conference Call Dates 2Health News:US Oncology to Report 2009 Second Quarter Operating Results 2Health News:University HealthSystem Consortium Recognized as a Company That Cares for Sixth Year in a Row 2Health News:Wonderbox Technologies(R) Releases Version 4.5 of the Enterprise System 2
Coude Foley Catheters (Latex) 2-Way Amber...
Silicone Elastomer-Coated Latex Foley Catheters 3-Way...
Silicone Foley Catheters 3-Way...
Midstream Catch Kits...
Medicine Products: